Fetal growth restriction due to maternal congenital hyperinsulinism associated with a novel variant in GLUD1 and intrauterine diazoxide exposure

Mirjam Dirlewanger1, Philippe Klee1, Emmanuelle Ranza2, Thomas Schalch3, Pierre Maechler4, Giacomo Gastaldi5, Michel Boulvain6, Valérie M Schwitzgebel1

1 Pediatric Endocrine and Diabetes Unit, Children’s University Hospital, Geneva, Switzerland. 2 Department of Genetic Medicine, University Hospitals, Geneva, Switzerland. 3 Department of Molecular Biology, Geneva University Medical Center, Geneva, Switzerland. 4 Department of Cell Physiology and Metabolism, Geneva University Medical Center, Geneva, Switzerland. 5 Division of Endocrinology, Diabetes, Hypertension and Nutrition, University Hospitals, Geneva, Switzerland. 6 Department of Gynecology and Obstetrics, University Hospitals, Geneva, Switzerland

Authors have no conflict of interest

Introduction

Congenital hyperinsulinism (CHI) is a rare disease due to an inappropriate secretion of insulin by pancreatic β-cells. Most forms are due to loss-of-function mutations of ABCB8 or KCNJ11 genes, encoding the subunits of the K+ATP channel SUR1 and Kir6.2 (1-2). The second leading cause of CHI are gain-of-function mutations in the glutamate dehydrogenase (GDH) encoded by the GLUD1 gene associated with an impaired ammonia processing (Hyperinsulinism-hyperammonemia syndrome) (3). Hypoglycemia will typically occur after fasting or after ingestion of a protein meal. GDH mediates conversion of glutamate to alpha-ketoglutarate and ammonia (Figure 1) (4). These mutations are dominantly inherited or the novo. In contrast to most K+ATP channel mutations, patient with GLUD1 CHI respond to diazoxide treatment, a K+ATP channel activator, but little is known about the potential teratogenic effects of this treatment during pregnancy.

Objective and Method

We report the neonatal outcome after fetal diazoxide exposure (50 mg t.i.d, 3 mg/kg/d) in the case of a maternal CHI.

Whole exome sequencing with bioinformatical targeted analysis of nine of the eleven genes known to cause monogenic CHI (Table 1) and one of the gene attributed to Beckwith-Wiedemann Syndrome (CDKN2C) was performed in the mother. Direct DNA sequencing of GLUD1 was done in the newborn.

Results

Whole exome sequencing of the ten selected genes known to cause CHI revealed a maternal novel heterozygous missense GLUD1 variant c.1496G>T; p.(Gly499Val), predicted to be pathogenic (Figure 2). The mother was treated through the whole pregnancy with diazoxide 50 mg t.i.d and she presented one severe hypoglycemic episode at eleven weeks of gestation due to treatment omission. The newborn was born by cesarean section at 40 weeks of gestation with intrauterine growth restriction (IUGR), birth weight 2300g (~2SD), length 46 cm (~2SD), Head circumference 32.5 cm (~2SD) and no visible malformations. Early feeding was started to prevent potential hypoglycemia. The genetic analysis showed that the newborn was not carrying the maternal GLUD 1 variant. No structural anomalies were identified on the brain MRI done on day of life 10.

Discussion and Conclusion

This is the case of a newborn at risk of inherited CHI who was exposed in utero to diazoxide and to maternal hypoglycemic episodes. This newborn had a 50% risk of inheriting CHI and fortunately he was unaffected. Reports of fetal exposure to diazoxide are limited, but in the past intravenous diazoxide has been used in pregnant women for its hypotensive action with risks of placental hypoperfusion, fetal death and transient neonatal hyperglycemia (6), with concentrations in the placenta and fetus supposed to be the same as in the mother. We did not identify postnatal glycaemic deregulations in the newborn. However the newborn presented with IUGR, which could be due to limited metabolic fuel in the context of maternal and fetal hypoglycemia, an uteroplacental insufficiency or to a direct deleterious effect of diazoxide on the fetal growth. IUGR per se is a risk factor for hypoglycemia, for structural brain changes and for impaired cognition.

In conclusion, no structural brain anomalies attributable neither to teratogenicity of diazoxide, hypoglycemia nor to IUGR were observed on the brain MRI, however this child is at risk of neurodevelopmental/cognitive impairment and will have to be followed long-term. Functional MRI, investigations of learning and memory skills will have to be repeated.

References: